Compare Omnicom Group Inc. (OMC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Omnicom Group Inc. trades at $79.2 (market cap $22.58B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Omnicom Group Inc. pays a 4.04% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Omnicom Group Inc. nearer its low. Which is the better fit depends on your goals.
| OMC | XBI | |
|---|---|---|
Market Cap | $22.58B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $85.80 | $164.28 |
52-Week Low | $67.27 | $85.16 |
Enterprise Value | $29.80B | — |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $79.21, down 3.08% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, beating expectations with $1.90 EPS versus $1.82 expected, but Q4 2025 missed at $2.59 versus $2.72. Revenue growth is strong, reaching $17.27 billion in 2025, though net income was negative $54.50 million due to elevated taxes. Analyst consensus is mixed with 32% buy ratings and a $105.75 price target, representing significant upside. Recent news highlights major client wins including IBM's global media account and partnerships with Netflix and Disney.
OMC presents a value opportunity with a low P/E of 12.16 and P/S of 0.96, trading below analyst targets. The advertising holding company benefits from AI platform expansion and strategic partnerships, but faces margin pressure and intense competition. Near-term catalysts include Q2 2026 earnings on July 28, 2026, where the company must deliver on the expected $2.58 EPS to maintain investor confidence amid current bearish sentiment.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
